Gsk and xenoport receive FDA approval for horizant for postherpetic neuralgia
XenoPort, 06/08/2012
GlaxoSmithKline plc (GSK) and XenoPort, Inc. announced that the United States (US) Food and Drug Administration (FDA) has approved Horizant (gabapentin enacarbil) Extended–Release Tablets for the management of postherpetic neuralgia (PHN) in adults.



